OncoMatch/Clinical Trials/NCT07140679
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Official title: A Phase II Trial of Adjuvant Toripalimab in High Risk Localized Colon Cancer With Mismatch Repair Deficiency
Is NCT07140679 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies Toripalimab for localized colon carcinoma.
Treatment: Toripalimab — This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MLH1 loss
Required: MSH2 loss
Required: MSH6 loss
Required: PMS2 loss
Disease stage
Required: Stage IIB, IIC, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: neoadjuvant therapy for dMMR colon cancer
Neoadjuvant treatment for dMMR colon cancer
Cannot have received: immune checkpoint inhibitor
Prior treatment with any immune checkpoint inhibitor
Lab requirements
Blood counts
ANC ≥ 1,000 /mcL; platelets ≥ 75,000 / mcL; hemoglobin ≥ 9 g/dL or ≥ 5.0 mmol/L (transfusion allowed to obtain adequate hemoglobin)
Kidney function
Creatinine ≤ 1.5 x ULN or measured or calculated creatinine clearance ≥ 40 mL/min for patient with creatinine levels > 1.5 x institutional ULN
Liver function
Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN; AST and ALT ≤ 3 x ULN; alkaline phosphatase ≤ 3 x ULN
ANC ≥ 1,000 /mcL; platelets ≥ 75,000 / mcL; hemoglobin ≥ 9 g/dL or ≥ 5.0 mmol/L; creatinine ≤ 1.5 x ULN or CrCl ≥ 40 mL/min; total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN; AST and ALT ≤ 3 x ULN; alkaline phosphatase ≤ 3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory Decatur Hospital · Atlanta, Georgia
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
- Emory Johns Creek Hospital · Johns Creek, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07140679 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant therapy for dMMR colon cancer, immune checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require MLH1?
Yes, MLH1 loss is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 loss is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 loss is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIB or IIC or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify